Home
NICE Guidance
Conditions and diseases
Cancer
Ovarian cancer
Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer
Technology appraisal guidance [TA389]
Published:
27 April 2016
Guidance
Tools and resources
Information for the public
History
Do no do examples
Do no do examples for Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer
Title
Year published
Impact Level
No results could be found